Hera BioLabs utilizes enabling gene editing technologies for preclinical discovery. We provide our clients with exceptional services, preclinical models off-the-shelf and gene editing tools for early drug development applications. Combined with our experienced staff & state-of-the-art facilities we ensure high quality data delivered. Hera’s platform in vivo model, the SRG rat, is a SCID rat on the Sprague-Dawley background harboring a double knockout for the Rag2 and Il2rgamma genes with applications in oncology, immuno-oncology and other areas of pharmacology/toxicology.  Our platform gene editing technologies are the piggyBac transposon, and the Cas-CLOVER targeted nuclease system with a broad application range in preclinical model development.

Preclinical Oncology

Leveraging our enabling gene editing technologies, Hera offers differentiated products and services for both in vitro and in vivo oncology and immuno-oncology. Our in vitro capabilities include efficacy screening and genome editing for new model creation. The OncoRat is a reliable, efficient & robust complement to in vivo mouse xenograft models. As evidenced in our case studies OncoRat is a powerful host for new tumor model and PDX creation. While the OncoRat is still under development humanization, cutting edge services are applied to the gold standard NSG mouse for immuno-oncology studies.

Gene Editing

Gene editing technologies can enable valuable model creation for preclinical studies as demonstrated by the OncoRat and cell line engineering case studies. With access to Hera’s portfolio, piggyBac transposase and the CRISPR-like nuclease, Cas-CLOVER, targeting your gene of interest is right at your fingertips through our reagent products or gene editing services. With over a decade of validation and IP development these technologies have broad applications and clear freedom to operate.

Praise for Hera

“The tumor uptake rate was to 80-100%, which is a huge advantage because what we could achieve as a statistical significance with 8-12 mice, can be achieved with 5-6 OncoRats.” — Ramesh Narayanan, Ph.D., Associate Professor of Medicine & Hematology at the University of Tennessee Health Science Center.
“(The) Cas-CLOVER hybrid gene editing system fuses a functionally inactive Cas9 to the site-specific nuclease, Clo51. Cas-CLOVER is targeted using a set of two distinct gRNAs, operating like CRISPR-Cas9, but (the) system has the exquisite specificity of type IIS nucleases and causes no or very few off-target mutations. We can use this high-fidelity system to safely develop off-the-shelf CAR T-cell products.” Devon J. Shedlock, Ph.D., vice president, preclinical development, Poseida Therapeutics. GEN Article True CRISPR: A Genetic Genre with Novel Twists

Our Blog: Preclinical Models & Gene Editing News

Check out the latest updates from our quarterly newsletter which provides information on new R&D, publications, model development & industry trends.
  • Cas-CLOVER™ – the clean alternative to CRISPR/Cas9 for gene editing in drug discovery and development - Key Points Cas-CLOVER is a cleaner gene editing alternative to CRISPR/Cas9 for gene editing in drug discovery Similar targeted mutagenesis rates can be achieved as compared with CRISPR/Cas9 Cas-CLOVER demonstrates high fidelity with no detectable off-targets Issued patents cover Cas-CLOVER (and TAL-CLOVER) enabling clear freedom-to-operate Hera is offering evaluations opportunities for Cas-CLOVER, which can convert into full research licenses with… Continue Reading >
  • OncoRat® featured in Clinical Cancer Research for prostate cancer studies - Improving Preclinical Anticancer Studies Using Rat Xenograft Model Systems: A case study of SRG OncoRat tumor xenografts from a Clinical Cancer Research publication (paper link)  Using the SRG OncoRat and xenograft validation services from Hera BioLabs, researchers were able to: Collect and validate an efficient, human relevant model system Confirm and compare data in the OncoRat with NSG mice Determine lead… Continue Reading >
  • The OncoRat® is the ideal host for patient-derived xenografts of ovarian cancer cells - Ovarian cancer is the most lethal gynecological cancer in the United States. Advances in cytotoxic, platinum-based chemotherapeutics combined with tumor resection surgery allows approximately 80% of these patients to achieve remission. Unfortunately, the vast majority have a tumor recurrence within 12-24 months and relapsed ovarian cancer is recognized as being universally incurable1-2.   Large genomic analyses of ovarian tumors, using… Continue Reading >